PCSK9 and androgen insensitivity syndrome: A total of 156 AIS patients with a history of CHD and symptom onset within 24 h will be recruited and randomly assigned to either the PCSK9 inhibitor combined with statin treatment group (PI group) or the statin monotherapy group (AT group).